Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.47 |
| ▸ | ALB | P02768 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | TK1 | P04183 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6507824 | 0.90 | ABL1 (0.47) | ABL1RIN1ALBALDH1A1LMNA | |
| SCHEMBL4288550 | 0.86 | ABL1 (0.47) | ABL1RIN1ALBALDH1A1LMNA | |
| SCHEMBL4288553 | 0.86 | ABL1 (0.47) | ABL1RIN1ALBALDH1A1LMNA | |
| SCHEMBL4288554 | 0.86 | ABL1 (0.47) | ABL1RIN1ALBALDH1A1LMNA | |
| SCHEMBL5953793 | 0.82 | ABL1 (0.47) | ABL1RIN1ALBALDH1A1LMNA | |
| SCHEMBL20633178 | 0.82 | ABL1 (0.47) | ABL1RIN1ALBALDH1A1LMNA | |
| SCHEMBL5953796 | 0.82 | ABL1 (0.47) | ABL1RIN1ALBALDH1A1LMNA | |
| SCHEMBL3451324 | 0.82 | ABL1 (0.47) | ABL1RIN1ALBALDH1A1LMNA | |
| SCHEMBL14389424 | 0.82 | ABL1 (0.47) | ABL1RIN1ALBALDH1A1LMNA | |
| SCHEMBL23696944 | 0.80 | ABL1 (0.45) | ABL1RIN1ALBALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105186-A1 | Beta-L-N4-Hydroxycytosine Deoxynucleosides and their use as Pharmaceutical Agents in the Prophylaxis or Therapy of Viral Diseases | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105186-A1 | Beta-L-N4-Hydroxycytosine Deoxynucleosides and their use as Pharmaceutical Agents in the Prophylaxis or Therapy of Viral Diseases | TYMP, ENTPD5, NUDT1 | ABL1 3160/4885RIN1 4387/4885ALB 3936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.